Epinal Inc Unveils Breakthrough Semiconductor Electrochemical Biosensor

IRVINE, Calif., Nov. 11, 2026 /CourierPR/ -- Epinal, Inc., an Irvine, California-based company, has emerged from stealth mode to unveil its groundbreaking Semiconductor Electrochemical Biosensor (SEB). The technology, developed over six years, aims to revolutionize the detection of narcotics and disease biomarkers in human breath, offering rapid, non-invasive, and objective results.

The SEB combines advanced semiconductor engineering, electrochemical sensing, protein engineering, and artificial intelligence to create a highly sensitive and selective biosensor. This innovative platform is designed to be integrated into future screening and diagnostic devices, particularly in the form of low-cost, disposable, single-use breathalyzer cartridges. These cartridges will be used in various end markets, including breathalyzer manufacturers, healthcare, mobile computers, clinical smartphones, handheld Biotech & MedTech OEMs, and mobile phone manufacturers.

The SEB's potential impact is significant. For narcotics detection, the rapid, non-invasive, and objective results can change outcomes. In the realm of disease detection and diagnostics, the SEB enables the development of advanced medical breathalyzers capable of identifying diseases and tracking metabolic functions. This technology promises to revolutionize point-of-care testing by providing early-stage, non-invasive detection and monitoring of disease biomarkers, eliminating the need for needles or complex laboratory infrastructure.

According to Mike Neshat, founder, Executive Chairman, and Chief Strategy Officer of Epinal, Inc., the company's goal is to make the world a better, safer, and healthier place by developing this disruptive technology.

Mark Wong, Co-Founder and Chief Executive Officer of Epinal, Inc., echoed Neshat's sentiments.

Epinal, Inc. is now focused on refining its technology to ensure its readiness for production in 2028. The company's leadership team, which includes Neshat, Wong, and Chief Operating Officer Dwight Dunagan, brings decades of experience in building electronics and semiconductor companies from concept to commercialization. Dunagan's background spans law enforcement, behavioral healthcare, and organizational leadership, providing a well-rounded approach to the company's mission.

The SEB's potential applications are vast, from law enforcement to healthcare. By enabling rapid and accurate detection of narcotics and disease biomarkers, the technology could significantly improve public safety and health outcomes. As the company moves closer to production, the SEB is poised to transform the way we approach screening and diagnostics, offering a more accessible and efficient solution for both individuals and healthcare providers.